BioEclip

BioEclipse Therapeutics is a clinical-stage oncology company that uses its proprietary platform technology to develop the next generation of immuno-oncology therapeutics. It has harnessed a refined understanding of the human immune system, including why the body's defenses so often ignore cancerous cells and tumors. The company pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result is a multi-mechanistic, targeted treatment intended to eradicate cancer cells and protect patients from relapse and recurrence through a durable immune response, with a focus on resistant and recurrent solid tumors regarded as virtually untreatable.